Background
BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) was a phase III randomized open-label trial (n=410) evaluating the addition of atezolizumab (anti-PD-L1) to the GOG-240 standard backbone of bevacizumab plus platinum-based chemotherapy in treatment-naive metastatic, persistent, or recurrent cervical cancer. It built directly on GOG-240, testing whether IO augmentation of the established bev-chemo standard improves survival.
Interventions and follow up
Arm A (control): Cisplatin 50 mg/m² (or carboplatin AUC 5) + paclitaxel 175 mg/m² + bevacizumab 15 mg/kg q21d until progression
Arm B (atezolizumab): Same backbone + atezolizumab 1200 mg q21d until progression
Primary endpoints: PFS and OS (dual primary)
Median follow-up: 32.9 months
Arm B (atezolizumab): Same backbone + atezolizumab 1200 mg q21d until progression
Primary endpoints: PFS and OS (dual primary)
Median follow-up: 32.9 months
Results
mPFS: 13.7 (atezo) vs 10.4 months; HR 0.62, 95% CI 0.49–0.78, P<.0001
Interim mOS: 32.1 vs 22.8 months; HR 0.68, 95% CI 0.52–0.88, P=.0046
ORR: 84% vs 75%; benefit consistent across PD-L1 and histology subgroups
Interim mOS: 32.1 vs 22.8 months; HR 0.68, 95% CI 0.52–0.88, P=.0046
ORR: 84% vs 75%; benefit consistent across PD-L1 and histology subgroups
Adverse events
Overall: Grade ≥3 AE 79% (atezo) vs 75% (control)
Immune-mediated: Grade 1–2 increased with atezolizumab (diarrhea, arthralgia, pyrexia, rash)
Bevacizumab-related: Hypertension and fistula similar between arms; no new safety signals from adding atezolizumab
Immune-mediated: Grade 1–2 increased with atezolizumab (diarrhea, arthralgia, pyrexia, rash)
Bevacizumab-related: Hypertension and fistula similar between arms; no new safety signals from adding atezolizumab
Conclusions
Adding atezolizumab to bevacizumab plus platinum-based chemotherapy significantly improved both PFS and OS in treatment-naive metastatic, persistent, or recurrent cervical cancer, establishing a new first-line option and demonstrating that IO augmentation of the bev-chemo backbone confers meaningful survival benefit.
Key Limitations
Open-label design; atezolizumab targets PD-L1 (not PD-1), making cross-trial comparison with KEYNOTE-826 indirect; no biomarker-selected subgroup analysis with pre-specified cutoffs; BEATcc uses bevacizumab in both arms while KEYNOTE-826 used it optionally; fistula risk with bevacizumab in irradiated patients relevant; the OS analysis was interim.
Clinical Context
BEATcc and KEYNOTE-826 both established IO plus chemo ± bevacizumab as the new standard for first-line metastatic/recurrent cervical cancer; BEATcc uses bevacizumab mandatorily in both arms while KEYNOTE-826 permitted no-bev patients. KEYNOTE-826 (FDA-approved 2021) and BEATcc (Lancet Dec 2023) form the evidence base for guideline-recommended IO-containing first-line regimens. BEATcc adds specific evidence for atezolizumab augmenting the bevacizumab backbone, supporting a class effect of PD-1/PD-L1 blockade in cervical cancer. ESMO guidance incorporates these regimens.